Nanjing Medlander Medical Technology Co (SHSE:688273) ROIC %: 12.04% (As of Mar. 2026)


SHSE:688273 Nanjing Medlander Medical Technology Co Ltd SHSE:688273
79 GF Score
Price ¥41.35
GF Value ¥34.95
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Nanjing Medlander Medical Technology Co ROIC %?

Nanjing Medlander Medical Technology Co SHSE:688273 +0.41% 79 ROIC % is 12.04% as of Mar. 2026. GuruFocus rates SHSE:688273 with a GF Score™ of 79/100 and a GF Value™ of ¥34.95 (Modestly Overvalued). The stock has 7 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Nanjing Medlander Medical Technology Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was 12.04%.

As of today (2026-07-06), Nanjing Medlander Medical Technology Co's WACC % is 16.03%. Nanjing Medlander Medical Technology Co's ROIC % is 11.57% (calculated using TTM income statement data). Nanjing Medlander Medical Technology Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Nanjing Medlander Medical Technology Co  (SHSE:688273) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Nanjing Medlander Medical Technology Co's WACC % is 16.03%. Nanjing Medlander Medical Technology Co's ROIC % is 11.57% (calculated using TTM income statement data). Nanjing Medlander Medical Technology Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Nanjing Medlander Medical Technology Co ROIC % Related Terms


Nanjing Medlander Medical Technology Co ROIC % Historical Data

* Premium members only.

The historical data trend for Nanjing Medlander Medical Technology Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Medlander Medical Technology Co ROIC % Chart

Nanjing Medlander Medical Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial 63.57 53.31 20.18 18.98 13.75

Nanjing Medlander Medical Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.09 16.66 17.01 0.40 12.04

SHSE:688273 vs ABT, SYK, MDT: ROIC % Comparison

For the Medical Devices subindustry, Nanjing Medlander Medical Technology Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing Medlander Medical Technology Co ROIC % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Medlander Medical Technology Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Nanjing Medlander Medical Technology Co's ROIC % falls into.


SHSE:688273
79GF Score
Nanjing Medlander Medical Technology Co Ltd SHSE:688273
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Medlander Medical Technology Co ROIC % Calculation

Nanjing Medlander Medical Technology Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=101.767 * ( 1 - 6.13% )/( (612.205 + 777.699)/ 2 )
=95.5286829/694.952
=13.75 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1546.622 - 95.717 - ( 894.977 - max(0, 162.957 - 1001.657+894.977))
=612.205

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1629.267 - 141.538 - ( 816.451 - max(0, 220.779 - 930.809+816.451))
=777.699

Nanjing Medlander Medical Technology Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=98.288 * ( 1 - 5.37% )/( (777.699 + 767.431)/ 2 )
=93.0099344/772.565
=12.04 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1629.267 - 141.538 - ( 816.451 - max(0, 220.779 - 930.809+816.451))
=777.699

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1617.146 - 115.907 - ( 788.001 - max(0, 188.504 - 922.312+788.001))
=767.431

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 12.04% mean?
Nanjing Medlander Medical Technology Co (SHSE:688273) has a ROIC % of 12.04% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Nanjing Medlander Medical Technology Co and its competitors.
Is Nanjing Medlander Medical Technology Co's ROIC % too high?
Nanjing Medlander Medical Technology Co's current ROIC % is 12.04%. The Medical Devices & Instruments industry median ROIC % is 1.26. Nanjing Medlander Medical Technology Co's value of 12.04% is 859.4% above this industry median. Overall, Nanjing Medlander Medical Technology Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Medlander Medical Technology Co's ROIC % compare to ABT and SYK?
Nanjing Medlander Medical Technology Co's ROIC % of 12.04% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROIC % is 1.26. Nanjing Medlander Medical Technology Co's value of 12.04% is 859.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Medical Devices & Instruments company?
The median ROIC % among Medical Devices & Instruments companies is 1.26, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Medlander Medical Technology Co's current ROIC % of 12.04% is 859.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Nanjing Medlander Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median ROIC % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Medlander Medical Technology Co's current ROIC % is 12.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Medlander Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co (SHSE:688273) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥34.95, compared to a current price of ¥41.35 — trading 18.3% above its estimated fair value. The current ROIC % is 12.04% and 859.4% above the Medical Devices & Instruments industry median of 1.26. Nanjing Medlander Medical Technology Co's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Nanjing Medlander Medical Technology Co (SHSE:688273), the current ROIC % is 12.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing Medlander Medical Technology Co (SHSE:688273) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co stock appears to be overvalued. The current stock price of ¥41.35 is trading 18.3% above its estimated GF Value™ of ¥34.95. GuruFocus considers Nanjing Medlander Medical Technology Co to be Modestly Overvalued.

Key valuation signals for SHSE:688273:

  • ROIC %: 12.04%
  • GF Value™: ¥34.95 vs. price of ¥41.35 (18.3% above fair value)
  • GF Score™: 79/100 with 7 warning signs
  • Industry Position: 859.4% above the Medical Devices & Instruments median

No single metric tells the full story. See the SHSE:688273 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanjing Medlander Medical Technology Co Business Description

Address Fengzhan Road, No. 32, Building A2, Yuhuatai District, Jiangsu Province, Nanjing, CHN, 210012
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.
79GF Score

Get the complete analysis for SHSE:688273

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥41.35
Price
¥34.95
GF Value